| scholarly article | Q13442814 |
| P2093 | author name string | Lynne V McFarland | |
| P2860 | cites work | Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial | Q24655137 |
| Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial | Q28237525 | ||
| Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis | Q28277603 | ||
| Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial | Q29394639 | ||
| Assessment of Clostridium difficile-associated disease surveillance definitions, North Carolina, 2005. | Q30229124 | ||
| Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea | Q33222511 | ||
| Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease | Q44074819 | ||
| Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure | Q44539645 | ||
| Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting | Q44561271 | ||
| Predicting Clostridium difficile toxin in hospitalized patients with antibiotic-associated diarrhea | Q44586645 | ||
| Risk factors for Clostridium difficile colonisation and toxin production | Q44643840 | ||
| Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea | Q44836632 | ||
| Management of an outbreak of Clostridium difficile-associated disease among geriatric patients | Q45173709 | ||
| Prevalence and characteristics of bacteria and host factors in an outbreak situation of antibiotic-associated diarrhoea | Q45240121 | ||
| Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea | Q45264302 | ||
| Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system | Q45332183 | ||
| A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. | Q46408982 | ||
| Clostridium difficile--associated disease in a setting of endemicity: identification of novel risk factors | Q46812258 | ||
| Evidence for neuromodulation of enteropathogen invasion in the intestinal mucosa | Q46880715 | ||
| Amoxicillin-associated hemorrhagic colitis in the presence of Klebsiella oxytoca | Q46929380 | ||
| Revised nomenclature of Clostridium difficile toxins and associated genes | Q48712234 | ||
| Recommendations for surveillance of Clostridium difficile-associated disease | Q48920404 | ||
| Who are susceptible to pseudomembranous colitis among patients with presumed antibiotic-associated diarrhea? | Q51781587 | ||
| Treatment of Clostridium difficile infection | Q51894323 | ||
| Epidemiology, risk factors and treatments for antibiotic-associated diarrhea | Q52533461 | ||
| Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States | Q53232557 | ||
| Risk Factors for Early RecurrentClostridium difficile–Associated Diarrhea | Q54135344 | ||
| Clostridium difficile–associated Diarrhea in Heart Transplant Recipients: Is Hypogammaglobulinemia the Answer? | Q57569236 | ||
| A Randomized Formula Controlled Trial of Bifidobacterium lactis and Streptococcus thermophilus for Prevention of Antibiotic-Associated Diarrhea in Infants | Q58227623 | ||
| Emergence and Control of Fluoroquinolone-Resistant, Toxin A–Negative, Toxin B–Positive Clostridium difficile | Q58624276 | ||
| Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials | Q33255725 | ||
| Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide | Q33276804 | ||
| Empirical use of antibiotics and adjustment of empirical antibiotic therapies in a university hospital: a prospective observational study | Q33280031 | ||
| Pseudomembranous colitis: causes and cures | Q33545742 | ||
| Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec | Q34099215 | ||
| Probiotics in the Treatment and Prevention of Acute Infectious Diarrhea in Infants and Children: A Systematic Review of Published Randomized, Double-Blind, Placebo-Controlled Trials | Q34431156 | ||
| A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality | Q34472139 | ||
| Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease | Q34517039 | ||
| Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies | Q34549108 | ||
| Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence | Q34722890 | ||
| Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus | Q35073168 | ||
| Do infection control measures work for methicillin-resistant Staphylococcus aureus? | Q35799718 | ||
| Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity | Q35874779 | ||
| The importance of guidelines in the development and application of probiotics. | Q36002824 | ||
| Does eating yogurt prevent antibiotic-associated diarrhoea? A placebo-controlled randomised controlled trial in general practice | Q36156241 | ||
| A systematic review and meta-analysis of misuse of antibiotic therapies in the community. | Q36189865 | ||
| Probiotics, gut inflammation and barrier function | Q36220419 | ||
| Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea | Q36416873 | ||
| Recurrent clostridium difficile | Q36450803 | ||
| Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. | Q36493837 | ||
| Implications of the changing face of Clostridium difficile disease for health care practitioners | Q36812666 | ||
| Update on the changing epidemiology of Clostridium difficile-associated disease | Q37050248 | ||
| Antimicrobial-associated risk factors for Clostridium difficile infection | Q37051298 | ||
| The Maxwell Finland Lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile | Q37056651 | ||
| Evaluation of Clostridium difficile-associated diarrhea with a drug formulary change in preferred fluoroquinolones | Q37074054 | ||
| Recent advances in Clostridium difficile-associated disease. | Q37077926 | ||
| Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection | Q39760796 | ||
| The burden of Clostridium difficile in surgical patients in the United States | Q39827525 | ||
| Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C difficile-associated disease | Q40209068 | ||
| Antibiotic-associated diarrhea in a Turkish outpatient population: investigation of 288 cases | Q40510823 | ||
| Adverse effects of newer cephalosporins. An update | Q40858398 | ||
| The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America | Q41445493 | ||
| Nosocomial acquisition of Clostridium difficile infection | Q41877583 | ||
| Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain | Q42012422 | ||
| Annual incidence of MRSA falls in England, but C difficile continues to rise | Q42713237 | ||
| Comparison of the premier toxin A and B assay and the TOX A/B II assay for diagnosis of Clostridium difficile infection | Q43057129 | ||
| Clostridium difficile among hospitalized patients receiving antibiotics: a case-control study | Q43407358 | ||
| Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study | Q43517827 | ||
| Role of Candida in antibiotic-associated diarrhea | Q43749192 | ||
| Specific risk factors for Clostridium difficile-associated diarrhea: a prospective, multicenter, case control evaluation | Q43956735 | ||
| P433 | issue | 5 | |
| P921 | main subject | epidemiology | Q133805 |
| diarrhea | Q40878 | ||
| P1104 | number of pages | 16 | |
| P304 | page(s) | 563-578 | |
| P577 | publication date | 2008-10-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Future Microbiology | Q15759961 |
| P1476 | title | Antibiotic-associated diarrhea: epidemiology, trends and treatment | |
| P478 | volume | 3 |
| Q44205937 | "Since antibiotic therapy I suffer from chronic diarrhea" |
| Q64251453 | A Small In Vitro Fermentation Model for Screening the Gut Microbiota Effects of Different Fiber Preparations |
| Q38865456 | Acid-Suppressive Therapy and Risk of Infections: Pros and Cons |
| Q36167528 | Antibiotic treatment of diarrhoea is associated with decreased time to the next diarrhoea episode among young children in Vellore, India |
| Q40617771 | Antibiotic-associated diarrhea and the older dental patient: how do dentists respond? |
| Q31133607 | Benchmarking Sepsis Gene Expression Diagnostics Using Public Data. |
| Q34648317 | Care-seeking and management of common childhood illnesses in Tanzania--results from the 2010 Demographic and Health Survey |
| Q38620301 | Causes of hematochezia and hemorrhagic antibiotic-associated colitis in children and adolescents |
| Q34448285 | Chemical biology applied to the study of bacterial pathogens |
| Q38747097 | Clinical implications of antibiotic impact on gastrointestinal microbiota and Clostridium difficile Infection |
| Q37613674 | Clostridial toxins |
| Q41172353 | Clostridium butyricum combined with Bifidobacterium infantis probiotic mixture restores fecal microbiota and attenuates systemic inflammation in mice with antibiotic-associated diarrhea. |
| Q34311594 | Clostridium difficile and the microbiota |
| Q40353967 | Clostridium difficile cell wall protein CwpV undergoes enzyme-independent intramolecular autoproteolysis. |
| Q38592385 | Clostridium difficile infection in the pediatric transplant patient |
| Q92835483 | Clostridium difficile infection: review |
| Q35973168 | Colonization Resistance of the Gut Microbiota against Clostridium difficile |
| Q26752760 | Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections |
| Q35412870 | Compositional dynamics of the human intestinal microbiota with aging: implications for health. |
| Q49195473 | Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). |
| Q38080794 | Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) |
| Q26771995 | Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance |
| Q98772442 | Distribution and risk factor analysis for Clostridium difficile-associated diarrhea among hospitalized children over one year of age |
| Q90598918 | Do we use antibiotics judiciously enough? A study in Accident & Emergency Department of tertiary care hospital in Pakistan |
| Q30491976 | Early Antibiotic Exposure in Low-Resource Settings is Associated with Increased Weight in The First Two Years of Life |
| Q55078100 | Effect of a multispecies probiotic on reducing the incidence of antibiotic-associated diarrhoea in children: a protocol for a randomised controlled trial. |
| Q64072115 | Effects of Drugs and Excipients on Hydration Status |
| Q59280914 | Effects on intestinal microbiota of probiotic fermented milk used for prevention of antibiotic-associated diarrhoea |
| Q39174699 | Efficacy of flurbiprofen 8.75 mg spray in patients with sore throat due to an upper respiratory tract infection: A randomised controlled trial |
| Q37858531 | Emerging therapies for Clostridium difficile infections |
| Q35977064 | Enteral vancomycin and probiotic use for methicillin-resistant Staphylococcus aureus antibiotic-associated diarrhoea |
| Q42255277 | Epidemiology of adverse events and Clostridium difficile-associated diarrhea during long-term antibiotic therapy for osteoarticular infections |
| Q38448914 | Exploring the effects of galacto-oligosaccharides on the gut microbiota of healthy adults receiving amoxicillin treatment |
| Q54226920 | Feasibility of a Lactobacillus casei Drink in the Intensive Care Unit for Prevention of Antibiotic Associated Diarrhea and Clostridium difficile |
| Q35973224 | Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection |
| Q47856504 | Frequency of Antibiotic-Associated Diarrhea and Related Complications in Pediatric Patients Who Underwent Hypospadias Repair: a Comparative Study Using Probiotics vs Placebo |
| Q29616812 | Gut Microbiota in Health and Disease |
| Q26865880 | Gut microbiota and gastrointestinal health: current concepts and future directions |
| Q34522528 | High-throughput analysis of the impact of antibiotics on the human intestinal microbiota composition |
| Q42136589 | Human intestinal microbiota gene risk factors for antibiotic-associated diarrhea: perspectives for prevention. Risk factors for antibiotic-associated diarrhea |
| Q34889455 | Impact of galacto-oligosaccharides on the gut microbiota composition and metabolic activity upon antibiotic treatment during in vitro fermentation |
| Q26778722 | Interactions Between the Gastrointestinal Microbiome and Clostridium difficile |
| Q37374530 | Intestinal alkaline phosphatase prevents antibiotic-induced susceptibility to enteric pathogens. |
| Q55453214 | Intestinal candidiasis and antibiotic usage in children: case study of Nsukka, South Eastern Nigeria. |
| Q35998372 | Lactobacillus rhamnosus GG Intake Modifies Preschool Children's Intestinal Microbiota, Alleviates Penicillin-Associated Changes, and Reduces Antibiotic Use. |
| Q36999988 | Markers of Intestinal Inflammation, Not Bacterial Burden, Correlate With Clinical Outcomes in Clostridium difficile Infection |
| Q33728333 | Microbial and metabolic interactions between the gastrointestinal tract and Clostridium difficile infection |
| Q37548795 | Microbial composition in different gut locations of weaning piglets receiving antibiotics |
| Q34129392 | Microbial endocrinology: Host-microbiota neuroendocrine interactions influencing brain and behavior |
| Q92597190 | Molecular Characterization and Moxifloxacin Susceptibility of Clostridium difficile |
| Q37992488 | Nosocomial Diarrhea: A Review of Pathophysiology, Etiology, and Treatment Strategies |
| Q36696682 | PURLs: prescribing an antibiotic? Pair it with probiotics |
| Q26771942 | Part 2: Treatments for Chronic Gastrointestinal Disease and Gut Dysbiosis |
| Q26775596 | Pathogenic Microorganisms and Pancreatic Cancer |
| Q37056524 | Patient Perspectives on Fecal Microbiota Transplantation for Clostridium Difficile Infection. |
| Q104495284 | Phylogenomic analysis of Clostridioides difficile ribotype 106 strains reveals novel genetic islands and emergent phenotypes |
| Q35494124 | Prevalence and management of antibiotic associated diarrhea in general hospitals |
| Q38821454 | Probiotics Reduce the Risk of Antibiotic-Associated Diarrhea in Adults (18-64 Years) but Not the Elderly (>65 Years): A Meta-Analysis. |
| Q36567134 | Probiotics and the gut microbiota in intestinal health and disease |
| Q24186991 | Probiotics for the prevention of pediatric antibiotic-associated diarrhea |
| Q24235039 | Probiotics for the prevention of pediatric antibiotic-associated diarrhea |
| Q91644124 | Probiotics for the prevention of pediatric antibiotic-associated diarrhea |
| Q33586133 | Protective Effect of Carvacrol against Gut Dysbiosis and Clostridium difficile Associated Disease in a Mouse Model |
| Q35139342 | PrsW is required for colonization, resistance to antimicrobial peptides, and expression of extracytoplasmic function σ factors in Clostridium difficile. |
| Q39200063 | Randomised, double-blind, placebo-controlled studies on flurbiprofen 8.75 mg lozenges in patients with/without group A or C streptococcal throat infection, with an assessment of clinicians' prediction of 'strep throat'. |
| Q38654043 | Randomized, Controlled, Crossover trial of Prevention of Clindamycin-Induced Gastrointestinal Signs Using a Synbiotic in Healthy Research Cats. |
| Q91578342 | Randomized, controlled, crossover trial of prevention of antibiotic-induced gastrointestinal signs using a synbiotic mixture in healthy research dogs |
| Q40408914 | Recurrent Clostridium difficile Infection in Children: Patient Risk Factors and Markers of Intestinal Inflammation |
| Q47838749 | SYN-004 (ribaxamase), an oral beta-lactamase, mitigates antibiotic-mediated dysbiosis in a porcine gut microbiome model |
| Q38226331 | Saccharomyces boulardii CNCM I-745 in different clinical conditions |
| Q44147671 | Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial |
| Q47149248 | Scientific Opinion on the substantiation of a health claim related to fermented milk containing Lactobacillus casei DN-114 001 plus yoghurt symbiosis (Actimel®), and reduction of Clostridium difficile toxins in the gut of patients receiving antibi... |
| Q26779200 | Selective Manipulation of the Gut Microbiota Improves Immune Status in Vertebrates |
| Q57114716 | Short and long-term effects of a synbiotic on clinical signs, the fecal microbiome, and metabolomic profiles in healthy research cats receiving clindamycin: a randomized, controlled trial |
| Q39139601 | Small Molecules That Sabotage Bacterial Virulence |
| Q37074702 | Small-Molecule Inhibitors of toxT Expression in Vibrio cholerae |
| Q64100368 | Small-molecule inhibitor of HlyU attenuates virulence of Vibrio species |
| Q91235299 | Study protocol of a double-blind randomised placebo-controlled trial on the effect of a multispecies probiotic on the incidence of antibiotic-associated diarrhoea in persons with spinal cord injury |
| Q24621081 | Systematic review and meta-analysis of Saccharomyces boulardii in adult patients |
| Q33886149 | The Clostridium difficile cell wall protein CwpV is antigenically variable between strains, but exhibits conserved aggregation-promoting function |
| Q38055820 | The Role of Probiotics in the Prevention and Treatment of Antibiotic-Associated Diarrhea and Clostridium Difficile Colitis |
| Q28075770 | The Significance of the Enteric Microbiome on the Development of Childhood Disease: A Review of Prebiotic and Probiotic Therapies in Disorders of Childhood |
| Q38246711 | The early use of appropriate prophylactic antibiotics in susceptible women for the prevention of preterm birth of infectious etiology |
| Q57245618 | The use of probiotics in gastrointestinal diseases |
| Q34231180 | Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis |
| Q34144918 | Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review |
| Q38842526 | Watchful Waiting for Cases of Pediatric Otitis Media: Modeling Parental Response to Physician Advice |
Search more.